We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Reserachers illuminate molecular player in morphine addiction and rare disease
News

Reserachers illuminate molecular player in morphine addiction and rare disease

Reserachers illuminate molecular player in morphine addiction and rare disease
News

Reserachers illuminate molecular player in morphine addiction and rare disease

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Reserachers illuminate molecular player in morphine addiction and rare disease"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

In a remarkable "two for one" discovery, scientists from the Florida campus of The Scripps Research Institute (TSRI) have illuminated a key molecular player in the addictive effects of morphine in animal models.


Interestingly, the protein—known as neurofibromin 1 (NF1)—is also known to be disrupted in an inherited disorder called neurofibromatosis type 1 (also called von Recklinghausen's disease), in which patients suffer from the growth of benign tumors beneath the skin, chronic pain, mild learning disabilities and an elevated risk of developing cancers.


See Also: Novel compound halts cocaine addiction and relapse behaviors


"We were searching for proteins that influence the long-term effects of opioids," said TSRI Professor Kirill Martemyanov. "In the short-term, opioids kill pain, but we were curious about mechanisms that lead to long-term adaptations that ultimately result in addiction. We screened for proteins that might possibly be involved in this process and what emerged was NF1."


The study, recently published in Current Biology, describes how NF1 influences opioid response through its impact on a signaling protein known as Ras in a part of the brain called the striatum, which is involved in decision making and reward.


When the researchers deleted NF1 in striatal neurons of animal models, opioids failed to engage Ras and its downstream signaling reactions, dramatically diminishing the addictive effects of morphine.


"One of the peculiar symptoms of neurofibromatosis type 1 is that patients often suffer from chronic, unexplained pain," said Martemyanov. "Given that the endogenous opioid system is involved in controlling pain sensitivity and the role of NF1 protein in mediating signaling of opioid receptors, it makes sense that if the mechanism is broken pain, might become an issue."


Learn more: Studies: Addiction starts with an overcorrection in the brain


He also noted the results suggest potential therapies for both conditions: "If you came up with a strategy to inhibit NF1 activity, perhaps the opioids won't be as addictive; but for those suffering from the neurofibromatosis, bypassing NF1 to activate Ras by receptors may be interesting to explore."


Note: Material may have been edited for length and content. For further information, please contact the cited source.


Scripps Research Institute   press release


Publication

Xie K et al. NF1 Is a Direct G Protein Effector Essential for Opioid Signaling to Ras in the Striatum.   Current Biology, Published Online October 20 2016. doi: 10.1016/j.cub.2016.09.010


Advertisement